Methods and systems for treating cell proliferation disorders with psoralen derivatives

Patent metadata

Field	Value
Publication number	US-11452884-B2
Application number	US-201815876401-A
Country	US
Kind code	B2
Filing date	Jan 22, 2018
Priority date	Jun 19, 2014
Publication date	Sep 27, 2022
Grant date	Sep 27, 2022

Abstract

Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof;and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

First claim

The invention claimed is:

1. A method for treating a cell proliferation disorder in a subject in need thereof, comprising:
(1) administering to the subject a psoralen compound selected from the group consisting of compounds having the following formulas:

that effects a predetermined cellular change when activated; and
(2) applying an initiation energy from an initiation energy source to the subject, activating the psoralen compound in situ, thus causing the predetermined cellular change to occur, wherein occurrence of the predetermined cellular change causes an increase or decrease in a rate of cell proliferation to treat the cell proliferation disorder,
wherein a plasmonics-active agent is not administered.

2. The method of claim 1 , wherein the psoralen compound is

3. A method for treating a cell proliferation disorder in a subject in need thereof, comprising:
(1) administering to the subject one or more energy modulation agents and a psoralen compound selected from the group consisting of compounds having the following formulas:

that effects a predetermined cellular change when activated; and
(2) applying an initiation energy from an initiation energy source to the subject,
wherein the one or more energy modulation agents convert the initiation energy applied to UV-A or visible energy, which then activates the psoralen compound in situ,
thus causing the predetermined cellular change to occur, wherein occurrence of the predetermined cellular change causes an increase in rate or decrease in rate of cell proliferation to treat the cell proliferation disorder,
wherein a plasmonics-active agent is not administered.

4. The method of claim 3 , wherein the psoralen compound is

5. A method for producing an autovaccine in a subject, comprising:
(1) providing a population of target cells from the subject;
(2) treating the target cells ex vivo with a psoralen compound selected from the group consisting of compounds having the following formulas:

(3) activating the psoralen compound with a UV-A source to induce apoptosis in the target cells; and
(4) returning the apoptic cells back to the subject to induce an autovaccine effect against the target cells, wherein the apoptic cells cause an autovaccine effect,
wherein a plasmonics-active agent is not used.

6. The method of claim 5 , wherein the psoralen compound is

7. A method for treatment of skin cancer in a subject in need thereof, comprising:
administering a psoralen compound selected from the group consisting of compounds having the following formulas:

to the subject in a manner sufficient to provide the psoralen compound in the subject's bloodstream such that the psoralen compound is delivered to a vicinity of a skin lesion from the skin cancer; and
irradiating the subject's skin in a region containing the skin lesion with an irradiation source having limited penetration ability and a wavelength sufficient to activate the psoralen compound,
wherein a plasmonics-active agent is not administered.

8. The method of claim 7 , wherein the irradiation source wavelength is a UV wavelength.

9. The method of claim 8 , wherein the UV wavelength is UV-B radiation.

10. The method of claim 8 , wherein the UV wavelength is UV-A radiation.

11. The method of claim 7 , wherein the irradiation source wavelength is an IR wavelength and the activation of the psoralen compound takes place by a multiphoton absorption.

12. The method of claim 7 , wherein the psoralen compound is

13. The method of claim 1 , wherein the cell proliferation disorder is cancer.

14. The method of claim 13 , wherein the cancer is breast cancer.

15. The method of claim 3 , wherein the cell proliferation disorder is cancer.

16. The method of claim 15 , wherein the cancer is breast cancer.

Assignees

• Immunolight Llc
• Univ Duke

Inventors

• Toone Eric J
• Gooden David
• Bourke Jr Frederic A
• Walder Harold

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61N2005/0661

  ultraviolet · CPC title

• A61N5/0616

  Skin treatment other than tanning · CPC title

• C07D493/04

  Ortho-condensed systems · CPC title

• A61N5/0601

  Apparatus for use inside the body · CPC title